Literature DB >> 3691606

Cardiac and microcirculatory effects of different doses of prostaglandin E1 in man.

J H Wilkens1, H Wilkens, B Elger, F Cassidy, L Caspary, A Creutzig, J C Frölich.   

Abstract

A cumulative dose response to intravenous PGE1 was established in 12 healthy volunteers. Systolic time intervals, including pre-ejection period (PEP), the ventricular ejection time (VET) and the RR-interval, were continuously determined, and transcutaneous oxygen pressure (tcpO2) was recorded. RR-intervals fell in a dose dependent manner, reaching a significantly lower level at 128 ng.kg-1.min-1 of PGE1 (basal value 842 ms falling to 756 ms). PEP decreased from 89 ms to 74 ms and the ratio PEP/VET decreased from 35% to 30%, indicating increased myocardial contractility. The maximal increase in tcpO2 was 125% on the calf and 60% on the foot. The peak tcpO2 was observed at an infusion rate of 16 ng.kg-1.min-1 PGE1. A decline in tcpO2 was seen at infusion rates greater than 64 ng.kg-1.min-1 PGE1 indicating a decrease in skin perfusion. The results indicate that the effects of intravenous PGE1 on skin perfusion occur at a lower threshold than the increase in myocardial contractility. A maximal increase in skin perfusion can be achieved with doses of PGE1 devoid of systemic haemodynamic effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691606     DOI: 10.1007/bf00544556

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Femoral-artery infusion of prostaglandin E 1 in severe peripheral vascular disease.

Authors:  L A Carlson; I Eriksson
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

2.  Intravenous prostaglandin E1 in severe peripheral vascular disease.

Authors:  L A Carlson; A G Olsson
Journal:  Lancet       Date:  1976-10-09       Impact factor: 79.321

3.  A multi-clinical double blind study with PGE, (alpha-cyclodextrin clathrate) in patients with ischemic ulcer of the extremities.

Authors:  S Sakaguchi; A Kusaba; Y Mishima; K Kamiya; A Nishimura; K Furukawa; S Shionoya; M Kawashima; T Katsumura; A Sakuma
Journal:  Vasa       Date:  1978       Impact factor: 1.961

4.  Cardiovascular effects of prostaglandin E1.

Authors:  J Nakano; J R McCurdy
Journal:  J Pharmacol Exp Ther       Date:  1967-06       Impact factor: 4.030

5.  [Vital capillary microscopic examination and transcutaneous pO2-measurements by intravenous prostaglandin E1 infusion].

Authors:  H Heidrich; T Lammersen
Journal:  Dtsch Med Wochenschr       Date:  1985-08-23       Impact factor: 0.628

6.  Influence of indomethacin and of prostaglandin E1 on total and regional blood flow in man.

Authors:  J Nowak; A Wennmalm
Journal:  Acta Physiol Scand       Date:  1978-04

7.  Circulation parameters during intravenous and intra-arterial administration of increasing doses of prostaglandin E1 in healthy subjects.

Authors:  T Brecht; M Ayaz
Journal:  Klin Wochenschr       Date:  1985-12-02

8.  Effects of adrenergic receptor activation and blockade on the systolic preejection period, heart rate, and arterial pressure in man.

Authors:  W S Harris; C D Schoenfeld; A M Weissler
Journal:  J Clin Invest       Date:  1967-11       Impact factor: 14.808

9.  Detrimental effect of high-dose prostaglandin E1 in the treatment of ischemic ulcers.

Authors:  R S Rhodes; S E Heard
Journal:  Surgery       Date:  1983-06       Impact factor: 3.982

10.  A comparison of some pharmacological actions of prostaglandin E1, 6-oxo-PGE1 and PGI2.

Authors:  P G Adaikan; N Y Tai; L C Lau; S M Karim; S R Kottegoda
Journal:  Prostaglandins       Date:  1984-04
View more
  2 in total

1.  Effect of the technique for assisting renal blood circulation on ischemic kidney in acute cardiorenal syndrome.

Authors:  Shigeru Hanada; Yoshiaki Takewa; Toshihide Mizuno; Tomonori Tsukiya; Yoshiyuki Taenaka; Eisuke Tatsumi
Journal:  J Artif Organs       Date:  2011-10-21       Impact factor: 1.731

Review 2.  Prostaglandin E1 plus methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials.

Authors:  De-Qi Jiang; Shi-Hua Zhao; Ming-Xing Li; Li-Lin Jiang; Yong Wang; Yan Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.